openPR Logo
Press release

Netherton Syndrome Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

07-02-2024 08:52 PM CET | Health & Medicine

Press release from: ABNewswire

Netherton Syndrome Pipeline 2024 | FDA Approvals, Clinical

DelveInsight's, "Netherton Syndrome- Pipeline Insight, 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Netherton Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Netherton Syndrome Research. Learn more about our innovative pipeline today! @ Netherton Syndrome Pipeline Outlook [https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Netherton Syndrome Pipeline Report

* June 2024:- Daiichi Sankyo- A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome. This study will explore the safety, pharmacokinetics (PK), and early clinical signal efficacy of DS-2325a in adult patients with NS.
* June 2024:- Boehringer Ingelheim- This study is open to people with a skin disease called Netherton syndrome (NS). People can join the study if they are 12 years and older. The purpose of this study is to find out whether a medicine called spesolimab helps people with NS.
* DelveInsight's Netherton Syndrome pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Netherton Syndrome treatment.
* The leading Netherton Syndrome Companies such as TenNor Therapeutics, KBP Biosciences, Debiopharm, Destiny Pharmaa, and others.
* Promising Netherton Syndrome Therapies such as DS-2325a, QRX003, Spesolimab, and others.

Stay informed about the cutting-edge advancements in Netherton Syndrome Treatments. Download for updates and be a part of the revolution in genetic disorder care @ Netherton Syndrome Clinical Trials Assessment [https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Netherton Syndrome Emerging Drugs Profile

* QRX003: Quoin Pharmaceuticals

QRX003 is a topical lotion, formulated with a proprietary Invisicare Registered delivery technology, and contains a broad- spectrum serine protease inhibitor, whose mechanism of action is intended to perform the function of a specific protein, called LEKTI. The absence of LEKTI in Netherton patients leads to excessive skin shedding resulting in a highly porous and compromised skin barrier. QRX003 is designed to lead to a more normalized skin shedding process and the formation of a stronger and more effective skin barrier.

* SXR-1096: Sixera Pharma

SXR1096 is a first-in-class, potent and selective small molecule inhibitor of kallikreins 5, 7 and 14 (KLK5, 7 and 14). The compound is formulated in a proprietary skin cream formulation designed for daily use in patients with rare skin conditions. Due to the inborn lack of the protease inhibitor LEKTI, KLK 5, 7 and 14 are overactive in the outermost layer of the skin in patients with Netherton syndrome. These drug targets can best be reached by applying the pharmaceutical directly on the skin. The disease is manifest from birth and can be life threatening in newborns.

Learn more about Netherton Syndrome Drugs opportunities in our groundbreaking Netherton Syndrome Research and development projects @ Netherton Syndrome Unmet Needs [https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Netherton Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Netherton Syndrome Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Discover the latest advancements in Netherton Syndrome Treatment by visiting our website. Stay informed about how we're transforming the future of genetic disorder @ Netherton Syndrome Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Netherton Syndrome Pipeline Report

* Coverage- Global
* Netherton Syndrome Companies- TenNor Therapeutics, KBP Biosciences, Debiopharm, Destiny Pharmaa, and others.
* Netherton Syndrome Therapies- DS-2325a, QRX003, Spesolimab, and others.
* Netherton Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Netherton Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Netherton Syndrome Pipeline on our website @ Netherton Syndrome Drugs and Companies [https://www.delveinsight.com/sample-request/netherton-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Netherton Syndrome: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Netherton Syndrome - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II/III)
* QRX003: Quoin Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* SXR-1096: Sixera Pharma
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Netherton Syndrome Key Companies
* Netherton Syndrome Key Products
* Netherton Syndrome- Unmet Needs
* Netherton Syndrome- Market Drivers and Barriers
* Netherton Syndrome- Future Perspectives and Conclusion
* Netherton Syndrome Analyst Views
* Netherton Syndrome Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=netherton-syndrome-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Netherton Syndrome Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight here

News-ID: 3562563 • Views:

More Releases from ABNewswire

WellnessLifeClub74 Launches Revolutionary E-Commerce Platform with Exclusive Bundle Packs and VIP Customer Experience
WellnessLifeClub74 Launches Revolutionary E-Commerce Platform with Exclusive Bun …
New retail platform WellnessLifeClub74 debuts with an extensive collection of home essentials, trending gadgets, and hard-to-find items, offering unprecedented savings through innovative bundle packages. The company's unique VIP customer treatment program and curated selection of furniture, home decor, and wellness products are transforming the online shopping experience for discerning consumers. WellnessLifeClub74 has officially entered the e-commerce marketplace with a comprehensive platform that combines extensive product selection with personalized customer service typically
Intention Boutique Revolutionizes E-Commerce Through Live-Vetted Sellers and Values-Driven Marketplace Model
Intention Boutique Revolutionizes E-Commerce Through Live-Vetted Sellers and Val …
Innovative retail platform Intention Boutique challenges mass marketplace conventions by personally vetting every seller through live conversations-prioritizing authenticity and ethics over scale. The curated alternative serves intentional shoppers seeking transparency, non-toxic products, and purpose-driven commerce that honors small-batch craftsmanship. Revolutionary thinking in e-commerce emerges as Intention Boutique Inc demonstrates how values-driven marketplace models can successfully challenge mass retail conventions through authentic seller relationships and intentional commerce standards. The innovative platform addresses
Experience Africa's Greatest Wildlife Comeback: Mountain Gorillas Hit Record Numbers as East Africa's Premier Safari Destinations Open to International Travelers
Experience Africa's Greatest Wildlife Comeback: Mountain Gorillas Hit Record Num …
Thanks to decades of gorilla conservation and responsible eco-tourism, mountain gorilla populations in Uganda, Rwanda, Kenya, and Tanzania have reached a record high, making mountain gorilla trekking, Big Five safaris, and luxury eco-lodge stays more popular than ever. Discover curated African safari packages, secure gorilla trekking permits, and explore iconic parks like Bwindi Impenetrable and Volcanoes National Park. The story of Mountain gorilla conservation is Africa's top wildlife headline in 2025.
MAGA Stocks Undercard: MYSE, XBIO, ATON, ACXP, RDZN - Innovators Driving Next Tech, Blockchain, AI Wave - More Stocks Inside
MAGA Stocks Undercard: MYSE, XBIO, ATON, ACXP, RDZN - Innovators Driving Next Te …
In today's MAGA Stocks Undercard lineup, a select group of small-cap innovators are reshaping the landscapes of social media, biotech, and blockchain technology. These companies-each positioned at the forefront of next-generation disruption-are demonstrating renewed investor confidence and sector-wide momentum heading into Q4. Myseum Inc. (NASDAQ: MYSE) has emerged as a privacy-first social media disruptor following the release of its latest shareholder letter, highlighting major progress ahead of the fall launch of

All 5 Releases


More Releases for Netherton

Netherton Syndrome Market is expected to reach USD 2.5 billion by 2034
Netherton Syndrome is a rare, inherited autosomal recessive skin disorder caused by mutations in the SPINK5 gene, which encodes the serine protease inhibitor LEKTI. The condition is characterized by ichthyosiform erythroderma, hair shaft abnormalities (trichorrhexis invaginata), and immune system dysfunction, often leading to recurrent infections and severe allergic manifestations. The prevalence is estimated at 1 in 200,000 births worldwide, making it a challenging orphan disease to diagnose and treat. Download Full
Evolving Market Trends In The Netherton Syndrome Industry: Advancements In Serin …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations. What Is the Expected Netherton Syndrome Market Size During the Forecast Period? The market size of the Netherton syndrome has experienced significant growth over the recent years. It is projected to escalate from $1.15 billion in 2024 to $1.27 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.2%. The notable growth
Netherton Syndrome Pipeline, Therapeutics Assessment, Clinical Trials, Drugs, an …
DelveInsight's, "Netherton Syndrome Pipeline Insight 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Netherton Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Netherton Syndrome Research. Learn more about
Netherton Syndrome Clinical Trials, Pipeline Insights, Treatment Drugs, and Comp …
DelveInsight's, "Netherton Syndrome- Pipeline Insight, 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Netherton Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Netherton Syndrome Research. Learn more about
Netherton Syndrome Pipeline Drugs, FDA Approvals, and Companies 2024
DelveInsight's, "Netherton Syndrome- Pipeline Insight, 2024" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Netherton Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Netherton Syndrome Research. Learn more about
Netherton Syndrome Market Size, Share, Trends, Insights, Growth 2032
Introduction A. Overview of Netherton Syndrome Netherton syndrome is a rare genetic disorder that primarily affects the skin, hair, and immune system. This condition is characterized by ichthyosis linearis circumflexa (red, scaly skin), trichorrhexis invaginata (bamboo hair), and a predisposition to atopic conditions such as eczema, asthma, and allergies. The syndrome is caused by mutations in the SPINK5 gene, which encodes the LEKTI protein, crucial for skin barrier function. Due to